Summary We evaluated the effectiveness of supplementation with high dose of oral vitamin D3 to correct vitamin D insufficiency. We have shown that one or two oral bolus of 300,000 IU of vitamin D3 can correct vitamin D insufficiency in 50% of patients and that the patients who benefited more from supplementation were those with the lowest baseline levels. Introduction Adherence with daily oral supplements of vitamin D3 is suboptimal. We evaluated the effectiveness of a single high dose of oral vitamin D3 (300,000 IU) to correct vitamin D insufficiency in a rheumatologic population. Methods Over 1 month, 292 patients had levels of 25-OH vitamin D determined. Results were classified as: deficiency <10 ng/ml, insufficiency ≥10 to 30 ng/ml, and normal ≥30 ng/ml. We added a category using the IOM recommended cut-off of 20 ng/ml. Patients with deficient or normal levels were excluded, as well as patients already supplemented with vitamin D3. Selected patients (141) with vitamin D insufficiency (18.5 ng/ml (10.2-29.1) received a prescription for 300,000 IU of oral vitamin D3 and were asked to return after 3 (M3) and 6 months (M6). Patients still insufficient at M3 received a second prescription for 300,000 IU of oral vitamin D3. Relation between changes in 25-OH vitamin D between M3 and M0 and baseline values were assessed. Results Patients (124) had a blood test at M3. Two (2%) had deficiency (8.1 ng/ml (7.5-8.7)) and 50 (40%) normal results (36.7 ng/ml (30.5-5.5)). Seventy-two (58%) were insufficient (23.6 ng/ml (13.8-29.8)) and received a second prescription for 300,000 IU of oral vitamin D3. Of the 50/124 patients who had normal results at M3 and did not receive a second prescription, 36 (72%) had a test at M6. Seventeen (47%) had normal results (34.8 ng/ml (30.3-42.8)) and 19 (53%) were insufficient (25.6 ng/ml (15.2-29.9)). Of the 72/124 patients who receive a second prescription, 54 (75%) had a test at M6. Twenty-eight (52%) had insufficiency (23.2 ng/ml (12.8-28.7)) and 26 (48%) had normal results (33.8 ng/ml (30.0-43.7)). At M3, 84% patients achieved a 25-OH vitamin D level >20 ng/ml. The lowest the baseline value, the highest the change after 3 months (negative relation with a correlation coefficient r0−0.3, p00.0007). Conclusions We have shown that one or two oral bolus of 300,000 IU of vitamin D3 can correct vitamin D insufficiency in 50% of patients.
Introduction
Vitamin D insufficiency is highly prevalent [1] . There is a large amount of evidence that with a daily oral intake of 700 to 1,000 IU of vitamin D3, the often-recommended serum level of 20-30 ng/ml of 25-OH vitamin D is usually achieved and up to 20% of falls and fractures are prevented [2] [3] [4] [5] [6] . In epidemiological studies, this recommended level has been associated with decreased cardiovascular, oncologic, and rheumatologic diseases [7, 8] . However, several recent works also question these findings and suggest that we have been overestimating vitamin D insufficiency using high cut-offs (such as 30 ng/ml) and its consequences [9] [10] [11] .
Adherence with daily oral supplements of vitamin D3 is suboptimal, with 50-75% of the population on oral daily vitamin D supplementation still exhibiting vitamin D insufficiency depending of the dose administered [12, 13] . If vitamin D supplementation is taken less than 80% of the time, the benefits against fractures and falls are lost [12] .
We elected to evaluate the effectiveness of supplementation with a single high dose of oral vitamin D3 (300,000 UI) to correct vitamin D insufficiency, a simple procedure that has gained wide acceptance in Switzerland despite controversy and the lack of any formal demonstration of effectiveness.
Methods

Study design and subjects
Over 1 month (November 2009), 292 consecutive patients attending our Rheumatology Outpatient Clinic at the University Hospital of Lausanne (latitude 46.52°N) had their blood level of 25-OH vitamin D measured. 25-OH vitamin D levels were determined using radioimmunologic assay with extraction (25-hydroxyvitamin D 125 I RIA Kit, DiaSorin®): the first step involves rapid extraction of 25-OH vitamin D and other hydroxylated metabolites from serum with acetonitrile. Following extraction, the treated sample is then assayed using equilibrium RIA procedure based on an antibody with specificity to 25-OH vitamin D.
Patients were classified into one of the following categories according to their 25-OH vitamin D level: deficient with levels <10 ng/ml (<25 nmol/l), insufficient with levels ≥10 to <30 ng/ml (≥25 to 75 nmol/l), and normal with levels ≥30 ng/ml (≥75 nmol/l). These definitions were based on a widely recognized definition of insufficiency and deficiency [8] . They are not exactly the same as those used in the recent Endocrine Society and Institute of Medicine (IOM) recommendations [14, 15] . We then a posteriori added a category using the IOM recommended cut-off of 20 ng/ml [14] .
For the present study, only patients with vitamin D insufficiency (≥10 ng/ml to <30 μg/l) were considered. Patients with deficient or normal levels were excluded, as well as patients already supplemented with daily oral vitamin D3 or who had received a single high dose of oral or intramuscular vitamin D3 within the previous 6 months.
At baseline, all selected patients received a prescription for a single high dose of 300,000 IU of oral vitamin D3 (Vitamin D3 Streuli® 1 ml, Streuli Pharma SA, 8730 Uznach, Switzerland) for the non-supervised administration of vitamin D3. No guidance was given on how to take the vitamin D. They then were asked to return after 3 (M3) and 6 months (M6) for a new determination of their 25-OH vitamin D levels. Patients still insufficient (≥10 ng/ml to <30 μg/l) at M3 received a second prescription for another single high dose of 300,000 IU of oral vitamin D3 (Vitamin D3 Streuli® 1 ml). Patients with deficiency at M3 were excluded from further follow-up, as they were administered either higher or intramuscular supplementation of vitamin D3.
This study is aligned with the Lausanne University Hospital Ethics committee. No outside funds were necessary. All patients were orally informed and oral consent was mandatory but no written informed consent was signed.
Statistical analysis
Relation between changes in 25-OH vitamin D between M3 and M0 and baseline values and relation between changes between M6 and M3 and M3 values were assessed by linear regression with statistical significance for p value<0.05. All analyses were performed using Stata 12.0 statistical software (Stata Corp, College station, TX, USA).
Results
Two hundred ninety-two patients had their level of 25-OH vitamin D determined in November 2009 [13] . The details of the 25-OH vitamin D results of the total sample of the 292 patients have been published recently [13] . Briefly, 7% were deficient, 79% insufficient, and 14% had normal results. We excluded 124 patients for the present analysis, 20 patients who had previously received a single dose of 300,000 IU of vitamin D3 within the preceding 6 months and 104 patients who were currently taking daily oral vitamin D3 supplements. Of the remaining 168 patients, 16 patients had levels of <10 ng/ml and 11 patients had levels of ≥30 ng/ml. One hundred forty-one remaining patients (84%) presented with vitamin D insufficiency (84 patients with levels of ≥10 to <20 ng/ml and 57 patients with levels of ≥20 to <30 ng/ml). Patients' characteristics are in the Table 1 .
All patients were given a prescription for a single high dose of 300,000 IU of oral vitamin D3. Figures 1 and 2 give the flow of the patients and the main findings at months 3 and 6.
Vitamin D levels at month 3 (M3)
One hundred and twenty-four patients (88%) returned to our Rheumatology Clinic at 3 months to have their 25 There was a significant negative relation with a correlation coefficient r0−0.3, p00.0007: the lowest the baseline value, the highest the change after 3 months. Identical analysis was performed for differences between M6 and M3 25-OH vitamin D levels for 54 patients who received a second dose at 3 months. There was no more correlation between the differences and values 3 months before (r0−0.11, p00.43) (Fig. 3) .
Discussion
We previously have demonstrated that hypovitaminosis D was highly prevalent in a population of Swiss rheumatology outpatients in autumn, and that classic oral daily supplementation with vitamin D3 was inefficient, with 75% of the patients on oral supplementation either deficient or insufficient in vitamin D, probably secondary to poor adherence [13] . Another Swiss study demonstrated that less than 5% of the elderly who recently had suffered from a hip fracture had vitamin D levels higher than the recommended 30 ng/ml, and that about 70% of the European population is below this threshold [1] .
As normalization of vitamin D levels appears to have clear benefits in the general population, we decided to evaluate the true effectiveness of supplementation with a single oral high dose of vitamin D3 (300,000 IU) to correct vitamin D insufficiency. This is a simple procedure that has gained wide-spread acceptance in Switzerland, despite the lack of any formal demonstration of its effectiveness. We began this study in 2009, before there was any significant controversy about the benefits of single high doses of vitamin D3 without calcium supplementation on fracture occurrence [16] [17] [18] .
Even if approximately 50% of our patients achieved normal results at 3 months after a single high dose of vitamin D3, this still means that this level of supplementation was inadequate to correct insufficiency in the other half, even if the mean serum levels at month 3 were not much lower than the often recommended cut-off of 30 ng/ml. On the other hand, the 20 ng/ml cut-off recently recommended by the IOM was achieved by more than 80% and more than 90% of patients at months 3 and 6, respectively.
Pharmacokinetic studies show that 25-OH vitamin D levels peak at 7 to 21 days and, thereafter, decrease slowly [19, 20] . It is known that any incremental increase in 25-OH vitamin D is likely to be lower in those already replete prior to supplementation [21] . The results at 3 months are, interestingly, not very different from the levels attained on 800 IU of oral daily vitamin D3 in some studies, when patients are adherent to the prescription [22] . The patients who seemed to benefit more from supplementation were those with the lowest baseline levels. However, we were unable to predict normalization of vitamin D from baseline values.
We also were unable to predict the evolution of vitamin D levels after supplementation. About half of patients whose vitamin D levels had normalized by 3 months continued to exhibit normal levels at 6 months; meanwhile, by 6 months, a second prescription of 300,000 IU of oral vitamin D3, administered at M3, had normalized half of those insufficient at 3 months. These results are in congruence with the results of a recent study involving a smaller and older population of patients with vitamin D deficiency, where important individual variations were observed, despite the administration of a single high dose of 300,000 IU of vitamin D3 under supervision [23] .
Our study had four main limitations. First, it is impossible to know for sure whether our patients really took their supplementation as prescribed and how they took it, as the administration was not supervised and adherence was not evaluated. Second, we lost 36% of our subjects over the course of follow-up (12% by 3 months). Third, the relevance of our results and the conclusion we can draw from them are also limited by the fact that we didn't measure other parameters such as calcium (could be suggested for safety reason) or parathyroid hormone (could help to determine the individual optimal 25-OH vitamin D level). Fourth, we didn't evaluate vitamin D level before 3 months, and if we cannot exclude correction of the insufficiency before that time point as it has been strongly supported by the literature [17, 21] , the benefits would be nevertheless transient in this subgroup. Finally, it has been suggested that plasma concentrations of 25-OH vitamin D may be decreased by inflammation and therefore less reliable in patient with systemic inflammatory disease. We could not address this problem with our study design. However, it appears unlikely that inflammation would be a major parameter in a treated population with mostly mild or absent inflammation [24] .
On the other hand, this renders ours as a "real life" practical study that clearly demonstrates that a single high dose of vitamin D3 is insufficient to completely correct and avoid vitamin D insufficiency in this setting, if 30 ng/ml is the goal. In contrast, one or two oral boluses of 300,000 IU of vitamin D3 in autumn and winter was a good means of preventing the 25-OH vitamin D nadir that usually is observed in the spring, since the average level was definitely higher than 20 ng/ml. It also is possible that levels higher than 20 ng/ml (and lower than 30 ng/ml) are adequate in a rheumatologic population (with or without osteoporosis), as recent reviews of evidence suggest [8] . Indeed, evidence for optimal bone health relates to level between 20 and 25 ng/ml, higher levels mainly relate to muscle function.
Finally, as suggested in recent publications, daily vitamin D3 supplements, with or without co-administered calcium, are probably more physiological than single high doses of oral vitamin D3. Nevertheless, adherence often is low and the efficiency of such an approach appears limited, as we have observed in our population. There have been doubts that very high doses of vitamin D3 might be harmful. Indeed 100,000 IU seems to be effective in reducing the occurrence of falls and fractures but 300,000 to 500,000 IU have been shown to actually increase this risk [5, 17, 25] . Other studies suggest that single oral doses of 300,000 IU of vitamin D3 are safe and more effective than 800 IU per day to increase serum 25-0H vitamin D [26, 27] . Others suggest that vitamin D3 is more potent than vitamin D2 [28] . This area of controversy needs further evaluation and was not the purpose of our study. A single high dose of vitamin D3 is certainly appealing. However, the safety of such an approach still must be determined [17] , as must its modalities of application, to ensure correction of the insufficiency in as large a percentage of patients as possible.
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